ApprovedFDA approval

Pixclara (floretyrosine F 18)

Telix Pharmaceuticals (TLX)

Marketer take

A PET agent for telling recurrent glioma apart from treatment-related change, so neuro-oncologists, neuroradiologists and nuclear medicine sites are the audience, with tracer availability and reimbursement shaping adoption.

Sponsor company
Telix Pharmaceuticals (TLX)
Indication
To use with positron emission tomography to differentiate recurrent or progressive glioma from treatment-related change in conjunction with other diagnostic evaluations
Therapeutic area
Diagnostic imaging, Oncology
Event
FDA approval
Date
Sep 11, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move